Nirog Therapeutics is a drug design venture started by Verseon to address the need for oral anti-coagulation drugs. An effective blood thinner is applicable to a wide variety of indications ranging from atrial fibrillation and various chronic cardiac conditions to strokes and clot prevention following surgery.

Current therapies, such as warfarin, have significant side effects from long term use. In addition, patient response to warfarin is unpredictable and can induce uncontrolled bleeding if not monitored carefully and dose adjusted frequently. Three drugs, Pradaxa, Xarelto, and Eliquis, that have recently entered market also suffer from high bleeding risk and other undesirable side effects. As such, there is a continuing need for a safe oral blood thinner drug with low bleeding risk.

The market size for blood thinner drugs is very large and a number of major pharmaceutical companies are looking to in-license oral blood thinner candidates. Nirog has several novel blood thinner drug candidates with best-in-class characteristics. These candidates are currently successfully undergoing animal testing.